Oryzon Genomics S.A.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ORYZF research report →
About the company
Oryzon Genomics S. A. is a clinical-stage biopharmaceutical company dedicated to advancing epigenetics-based therapies for individuals battling cancer and central nervous system (CNS) conditions.
- CEO
- Carlos Manuel Buesa Arjol
- IPO
- 2020
- Employees
- 47
- HQ
- Cornellà de Llobregat, ES
Price Chart
- Market Cap
- $283.31M
- P/E
- -107.34
- P/S
- 55.76
- P/B
- 2.22
- EV/EBITDA
- -35.93
- Div Yield
- 0.00%
- Gross Margin
- 94.27%
- Op Margin
- -158.39%
- Net Margin
- -51.67%
- ROE
- -2.03%
- ROIC
- -1.99%
- Revenue
- $0 · -100.00%
- Net Income
- $-2,604,492 · 28.94%
- EPS
- $-0.04 · 38.16%
- Op Income
- $-6,416,519.5
- FCF YoY
- 81.98%
- 52W High
- $4.38
- 52W Low
- $3.03
- 50D MA
- $3.56
- 200D MA
- $3.47
- Beta
- 0.45
- Avg Volume
- 42
Get TickerSpark's AI analysis on ORYZF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our ORYZF coverage
Recent articles, reports, and earnings notes.
No research on ORYZF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ORYZF report →Similar companies
Peers in the same neighborhood.